T-Cell Transfer Therapy Targeting Mutant KRAS.
作者信息
Maoz Asaf, Rennert Gad, Gruber Stephen B
机构信息
USC Norris Comprehensive Cancer Center, Los Angeles, CA
Technion Carmel Medical Center, Haifa, Israel
出版信息
N Engl J Med. 2017 Feb 16;376(7):e11. doi: 10.1056/NEJMc1616637.
Abstract
摘要
相似文献
1
T-Cell Transfer Therapy Targeting Mutant KRAS.靶向突变型KRAS的T细胞转移疗法
N Engl J Med. 2017 Feb 16;376(7):e11. doi: 10.1056/NEJMc1616637.
2
T-Cell Transfer Therapy Targeting Mutant KRAS.靶向突变型KRAS的T细胞转移疗法
N Engl J Med. 2017 Feb 16;376(7):e11.
3
T-Cell Transfer Therapy Targeting Mutant KRAS.靶向突变型KRAS的T细胞转移疗法
N Engl J Med. 2017 Feb 16;376(7):e11. doi: 10.1056/NEJMc1616637.
4
Mutant RAS Calms Stressed-Out Cancer Cells.突变型RAS使应激的癌细胞平静下来。
Dev Cell. 2017 Jan 23;40(2):120-122. doi: 10.1016/j.devcel.2017.01.005.
5
Treatment of KRAS-Mutant Non-Small Cell Lung Cancer: The End of the Beginning for Targeted Therapies.KRAS 突变型非小细胞肺癌的治疗：靶向治疗新纪元的开端
JAMA. 2017 May 9;317(18):1835-1837. doi: 10.1001/jama.2017.3436.
6
KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries.散发性结直肠癌患者的KRAS和BRAF突变状态：来自两个不同地中海国家的数据。
Int J Biol Markers. 2011 Oct-Dec;26(4):276-7. doi: 10.5301/JBM.2011.8874.
7
The genetics and biology of KRAS in lung cancer.肺癌中KRAS的遗传学与生物学特性
Chin J Cancer. 2013 Feb;32(2):63-70. doi: 10.5732/cjc.012.10098. Epub 2012 Jul 2.
8
KRAS oncogene rearrangements and gene fusions: unexpected rare encounters in late-stage prostate cancers.KRAS 癌基因重排和基因融合：晚期前列腺癌中意想不到的罕见事件。
Cancer Discov. 2011 Jun;1(1):12-3. doi: 10.1158/2159-8274.CD-11-0045. Epub 2011 Jun 1.
9
Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.致癌性 KRAS 诱导的表皮调节素过表达有助于侵袭表型，是一种有前景的非小细胞肺癌治疗靶点。
Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.
10
A step towards treating KRAS-mutant NSCLC.迈向治疗KRAS突变型非小细胞肺癌的一步。
Lancet Oncol. 2013 Jan;14(1):3-5. doi: 10.1016/S1470-2045(12)70528-4. Epub 2012 Nov 28.
引用本文的文献
1
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer.泛RAS抑制剂与 polo样激酶1：结直肠癌中有前景的靶点
Oncogene. 2025 Aug;44(30):2565-2573. doi: 10.1038/s41388-025-03484-z. Epub 2025 Jul 4.
2
Tumor Antigens beyond the Human Exome.人类外显子组之外的肿瘤抗原。
Int J Mol Sci. 2024 Apr 25;25(9):4673. doi: 10.3390/ijms25094673.
3
KRAS inhibition in metastatic colorectal cancer: An update.转移性结直肠癌的 KRAS 抑制：更新。
Curr Opin Pharmacol. 2023 Feb;68:102343. doi: 10.1016/j.coph.2022.102343. Epub 2023 Jan 11.
4
Development and Application of Patient-Derived Cancer Organoidsin Clinical Management of Gastrointestinal Cancer: A State-of-the-Art Review.患者来源的癌症类器官在胃肠道癌临床管理中的开发与应用：最新综述
Front Oncol. 2021 Oct 29;11:716339. doi: 10.3389/fonc.2021.716339. eCollection 2021.
5
Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesions.T 细胞受体库多样性升高与肺鳞癌前病变的进展相关。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002647.
6
Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.克服胰腺导管腺癌的肿瘤微环境障碍以实现更好的治疗效果。
Adv Ther (Weinh). 2021 Jun;4(6). doi: 10.1002/adtp.202000262. Epub 2021 Apr 24.
7
High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.高亲和力寡克隆 TCR 定义了针对突变 KRAS-G12D 的有效过继性 T 细胞治疗。
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12826-12835. doi: 10.1073/pnas.1921964117. Epub 2020 May 27.
8
The era of immunogenomics/immunopharmacogenomics.免疫基因组学/免疫药物基因组学时代。
J Hum Genet. 2018 Jul;63(8):865-875. doi: 10.1038/s10038-018-0468-1. Epub 2018 May 21.
本文引用的文献
1
Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer.肿瘤浸润淋巴细胞、克罗恩样淋巴样反应与结直肠癌生存率
J Natl Cancer Inst. 2016 May 12;108(8). doi: 10.1093/jnci/djw027. Print 2016 Aug.
2
Statins and the risk of colorectal cancer.他汀类药物与结直肠癌风险
N Engl J Med. 2005 May 26;352(21):2184-92. doi: 10.1056/NEJMoa043792.
Zotero 插件